Xylometazoline (Xynosine, Otrivin) nasal spray

Xylometazoline is an alpha-adrenergic agonist that causes vasoconstriction of the arterioles of the nasal mucosa and conjunctiva.

  • It is used for the temporary relief in nasal and nasopharyngeal mucosal congestion in patients with allergic rhinitis.

Xylometazoline Dose in Adults

Dose in the treatment of Nasal congestion: Intranasal:

  • Drops (0.1%):

    • 2 to 3 drops are applied drops in each nostril after every 8 to 10 hours
  • Metered-dose spray (0.1%):

    • Single spray in each nostril after every 8 to 10 hours
  • Spray (0.05%, 0.1%):

    • 1 or 2 sprays are given in each nostril after every 8 to 10 hours

Xylometazoline Dose in Children:

  • Infants and children 6 months to 12 years of age:

    • 2 or 3 drops of 0.05% solution to nasal mucosa every 8 to 10 hours.
    • The dose should not be repeated for more than three times in 24 hours.
  • Infants younger than age 6 months

  • 1 drop of 0.05% solution in each nostril every six hours as needed under medical direction

Pregnancy Risk Factor: C

  • According to the manufacturer it is not recommended for use during pregnancy.

Xylometazoline use during breastfeeding:

  • It is unknown if xylometazoline excreted in breastmilk or not.
  • The manufacturer recommends that nursing mothers not be given xylometazoline.

Xylometazoline dose in Renal Disease:

  • No adjustment in the dose is necessary.

Xylometazoline Dose in Liver Disease:

  • No adjustment in the dose is necessary.

Less Common Side Effects of Xylometazoline Include:

  • Central nervous system:

    • Headache
  • Gastrointestinal:

    • Nausea
  • Local:

    • Application site burning
  • Respiratory:

    • Dry nose
    • Nasal discomfort

Contraindication to Xylometazoline Include:

  • Allergy reactions to xylometazoline and any component of the formulation
  • Patients who had to have transsphenoidal hypophysectomy (or surgery that exposed the dura mater) performed by a surgeon.
  • Narrow-angle glaucoma
  • Rhinitis sicca
  • Atrophic rhinitis

Warnings and precautions

  • Rebound your nasal congestion
    • Nasal congestion can recur, or worsen, if it is prolonged or repeated.
  • Cardiovascular disease
    • Patients with heart disease or hypertension should be cautious.
  • Diabetes mellitus:
    • Patients with diabetes mellitus should be cautious.
  • Thyroid disease:
    • Patients with thyroid disease should be cautious.
  • Prostatic hyperplasia/Urinary Obstruction:
    • Patients with prostatic hyperplasia or GU obstruction should be cautious.

Xylometazoline (United States: Not available): Drug Interaction

Risk Factor C (Monitor therapy)

Alpha1-Blockers

May diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1Agonists may antagonize Alpha1-Blocker vasodilation.

AtoMOXetine

May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.

Cannabinoid-Containing Products

May enhance the tachycardic effect of Sympathomimetics. Exceptions: Cannabidiol.

Doxofylline

Sympathomimetics may enhance the adverse/toxic effect of Doxofylline.

FentaNYL

Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.

Guanethidine

May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.

Solriamfetol

Sympathomimetics may enhance the hypertensive effect of Solriamfetol.

Sympathomimetics

May enhance the adverse/toxic effect of other Sympathomimetics.

Tricyclic Antidepressants

May enhance the therapeutic effect of Alpha1-Agonists. Tricyclic Antidepressants may diminish the therapeutic effect of Alpha1-Agonists.

Risk Factor D (Consider therapy modification)

Cocaine (Topical)

May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.

Esketamine

Decongestants (Nasally Administered) may diminish the therapeutic effect of Esketamine. Management: Patients who require a nasal decongestant on an esketamine dosing day should administer the nasal decongestant at least 1 hour before esketamine.

Linezolid

May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific dose adjustment recommendations are not presently available.

Risk Factor X (Avoid combination)

Ergot Derivatives

May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists. Exceptions: Ergoloid Mesylates; Nicergoline.

Iobenguane Radiopharmaceutical Products

Alpha1-Agonists may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.

Monoamine Oxidase Inhibitors

May enhance the hypertensive effect of Alpha1-Agonists. While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors. Refer to linezolid specific monographs for details. Exceptions: Linezolid; Tedizolid.

Tedizolid

May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.

Monitoring Parameters:

No monitoring parameters mentioned. 

How to administer Xylometazoline?

For intranasal use only.

  • First, blow nose to clear nostrils before using.
  • Then tilt the head slightly forward (for spray) or backward (for drops)
  • Then spray solution or apply drops into the affected nostril.
  • After usage of spray or drops inhale deeply.
  • Tip of the container should be wiped clean after each use.
  • Some products are needed to be primed before initial use.

Mechanism of action of Xylometazoline:

  • It stimulates the alpha-adrenergic receptors of the conjuntiva arterioles and the nasal mucosa, causing vasoconstriction

The nasal spray begins to work:

  • It causes vasoconstriction in the local area within 2 minutes

Duration of action:

  • It is up to 12 hours

International Brands of Xylometazoline:

  • Af-Care
  • Amidrin
  • Antazol
  • Balkis
  • Cirovin
  • Colirio Azul
  • Decon
  • Decozal
  • Ezybreth
  • Fastorik N
  • FLO Rapid Relief
  • Galazolin
  • Gelonasal
  • Hidropid
  • Huma-Metazol
  • Hysan
  • Nasan
  • NasenGel ratiopharm
  • NasenSpray ratiopharm
  • NasenTropfen ratiopharm
  • Nasoferm
  • Nasolin
  • Nasostop
  • Nazol N
  • Neusdruppels
  • Novin
  • Novorin
  • Olynth
  • Osco Xuzulex Nasal Spray
  • Otrinase
  • Otriven
  • Otrivin
  • Otrivina
  • Otrivine
  • Pen Ke Tong
  • Rhinidine
  • Rhinozol
  • Senziola
  • Sinuvin
  • Snup Stada
  • Tezoline
  • Tyzine
  • Xoline
  • Xylo-POS
  • Xylolin
  • Xylomaris
  • Xylomet
  • Xylovit
  • Xymelin
  • Balminil Decongest
  • Otrivin
  • Alpha-Adrenergic Agonist
  • Decongestant
  • Imidazoline Derivative

Xylometazoline Nasal Spray in Pakistan:

  • Lyzo - Alina
  • Nasavin - Cibex
  • Rhezole - Epla
  • Xlomet - Karachi chemical
  • Xolisan - Sante
  • Xylomed - Mediate
  • Xylonas - Geofman
  • Xynosine - Zafa

Xylometazoline (HCl) [Nasal Drops 5 ml]

Xlomet Karachi Chemical Industries

 

Xylometazoline (HCl) [Nasal Drops 0.05 %w/v]

Xlomet Karachi Chemical Industries
Xynosine C.F Zafa Pharmaceutical Laboratories (Pvt) Ltd.

 

Xylometazoline (HCl) [Nasal Spray 0.1 %w/v]

Lyzo Alina Combine Pharmaceuticals (Pvt) Ltd.
Xolisan Sante (Pvt) Limited
Xylomed Mediate Pharmaceuticals (Pvt) Ltd
Xylometazoline Karachi Chemical Industries
Xylonas Geofman Pharmaceuticals
Xynosine Zafa Pharmaceutical Laboratories (Pvt) Ltd.

Comments

NO Comments Found